SNPMiner Trials (Home Page)
Report for SNP rs1504982
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma
This study is designed to investigate whether the Phosphodiesterase 4 gene variability could be implicated in the salbutamol responsiveness in asthmatic children.
NCT03592212 Asthma Drug: Salbutamol MeSH:Asthma
HPO:Asthma
comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator VEMS value (BDR = 100 x [post-VEMS - pre-VEMS]/pre-VEMS) according to the genotype of the rs1504982.
Primary Outcomes
Description: comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator VEMS value (BDR = 100 x [post-VEMS - pre-VEMS]/pre-VEMS) according to the genotype of the rs1504982
Measure: pre- and post-bronchodilator VEMS value Time: Day 0Secondary Outcomes
Description: To identify other SNPs on PDE4 associated with the response (BDR) to salbutamol in childhood asthma.
Measure: Locating other regions of the PDE4 gene that may be associated with the response to salbutamol by gene mapping (using SNP tags) Time: Day 0Description: To identify other genes that could be associated with the phenotype of interest (BDR) by tagging other genes.
Measure: Screening other SNPs (other genes than PDE4) associated with the response to salbutamol in childhood asthma using SNP tags Time: Day 0